91.20Open91.20Pre Close0 Volume4 Open Interest175.00Strike Price0.00Turnover65.53%IV8.70%PremiumDec 20, 2024Expiry Date69.89Intrinsic Value100Multiplier28DDays to Expiry21.31Extrinsic Value100Contract SizeAmericanOptions Type0.9756Delta0.0013Gamma3.45Leverage Ratio-0.0648Theta0.1276Rho3.37Eff Leverage0.0387Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet